Article Text

Download PDFPDF
Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies

Statistics from


  • CC and DP contributed equally.

  • Contributors GF, AE-L, GB, CC and DP wrote the manuscript. CD-P, MS, JL, LT, CM-R, BR, PC, CT, WN, KV, TM, TL, AW, LM, KB, NG and DA revised the manuscript for intellectual content.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JL has received research grants and personal fees from Takeda pharmaceutical company. GF, CD-P, MS, LT, CM-R, BR, GB, CT, WN, KV, TM, TL, AW, LM, KB, NG, DA, AE-L, CC and DP declare that they have no conflict of interest.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.